NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球血管通路系統市場-預測(2021-2026)

Global Vascular Access System Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023151
出版日期 內容資訊 英文 122 Pages
商品交期: 最快1-2個工作天內
價格
全球血管通路系統市場-預測(2021-2026) Global Vascular Access System Market - Forecasts from 2021 to 2026
出版日期: 2021年07月06日內容資訊: 英文 122 Pages
簡介

2019 年全球血管通路系統市場價值 47.44 億美元,預測期內復合年增長率為 6.27%,到 2026 年將達到 72.59 億美元。據預測。

靜脈或動脈通過血管通路系統獲得。血管通路系統是一種醫療器械,用於進入血流以供應藥物、輸液、營養管理以及收集血管及其製品。這些血管通路管由乳膠、矽膠和其他物質製成。該程序需要在血管中放置一根硬塑料管,例如貴要靜脈和鎖骨下靜脈,以進行診斷測試和治療,例如化療、靜脈注射抗生素治療和靜脈營養。...包括採血、輸血、輸液和測量中心靜脈壓。在化療的情況下,血管通路導管裝置也被大量使用。

血液通過各種血管通路系統(例如插管、導管、外圍設備和端口)從人的血流中連續獲取或供應到人的血流中。這個過程減輕了患者持續的針刺壓力,並允許他們以無痛的方式抽血和給藥。與人體血流相關的疾病(例如腎功能衰竭、糖尿病和癌症)在全球日益流行,這對血管通路系統的需求產生了積極影響。

然而,與血管通路系統相關的高感染風險和嚴格的政府審批規定正在抑制血管通路系統市場的增長。在過去十年中,一些需要血管通路治療的慢性疾病的患病率有所增加。主要的慢性病包括癌症、腎衰竭和心臟病。還有一些與生活方式相關的疾病與慢性和非傳染性疾病有關,例如高血壓、糖尿病、肥胖症和抑鬱症,需要在住院期間進行重要治療。

本報告調查了全球血管通路系統市場,包括市場的基本結構、主要的促進/抑制因素、整體市場規模趨勢展望,按產品/用途/最終用戶/地區。提供詳細的趨勢、競爭條件、主要公司的簡介等。

目錄

第 1 章介紹

  • 市場定義
  • 市場細分

第二章調查方法

  • 調查數據
  • 先決條件

第 3 章執行摘要

  • 研究亮點

第 4 章市場動態

  • 市場驅動因素
  • 市場限制
  • 波特五力分析
    • 最終用戶的議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 競爭對手之間的敵對關係
  • 產業價值鏈分析

第 5 章血管通路系統市場分析:按產品分類

  • 簡介
  • 外周插入中心靜脈導管 (PICC)
  • 非隧道式中心靜脈導管
  • 隧道導管
  • 端口導管

第 6 章血管通路系統市場分析:按應用

  • 簡介
  • 靜脈抗生素治療
  • 輸血
  • 長期靜脈注射
  • 化療
  • 其他

第 7 章血管通路系統市場分析:按最終用戶

  • 簡介
  • 醫院和診所
  • 門診手術中心
  • 導管室

第 8 章血管通路系統市場分析:按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印度尼西亞
    • 其他

第九章競爭環境與分析

  • 主要公司和戰略分析
  • 初創企業和市場盈利能力
  • 企業併購(M&A)/合同/業務合作
  • 供應商競爭力矩陣

第 10 章公司簡介

  • Edwards Lifesciences Corporation
  • Baxter International Inc.
  • C.R. Bard, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Becton, Dickinson and Company
  • Teleflex Incorporated
  • Medtronic PLC
  • B.Braun Melsungen AG
  • Smiths Medical
  • Biomerics
目錄
Product Code: KSI061610470

The global vascular access systems market is evaluated at US$ 4.744 billion for the year 2019 growing at a CAGR of 6.27% reaching a market size of US$ 7.259 billion by the year 2026. Venous or arterial access is obtained through vascular access systems. Vascular Access Devices are medical equipment used to get ingress the bloodstream to supply medicines, administer fluids, nutritional components, and collection of blood vessels and their products. These vascular access tubes are made from latex, silicon, and other substances. The procedure involves placing rigid plastic tubes into blood vessels such as the basilic vein and subclavian vein to perform diagnostic tests and treatments such as chemotherapy, intravenous antibiotic treatment, and intravenous feeding. It includes blood sampling, blood transfusion, fluid infusion, and central venous pressure readings. The vascular access catheter devices are also significantly used in the case of chemotherapies.

The blood is obtained from or delivered to a person's bloodstream over a continuous period through different vascular access devices such as cannulae, catheters, peripherals, and ports. The procedure relieves patients from the continuous stress of needles and offers a painless method to draw blood or provide medication. The rising global prevalence of diseases such as kidney failure, diabetes, and cancer which involve the transfer of blood to and from the human body is positively impacting the demand for vascular access systems. High infection risk associated with vascular access devices and stringent government approval regulations restrains the growth of the vascular access systems market. Over the past decade, there has been a rise in the prevalence of several chronic diseases that need vascular access treatment. Some of the major chronic diseases include cancer, kidney failure, and heart diseases, among others. Along with these, there are several lifestyle disorders relating to chronic and non-communicable disease conditions, such as hypertension, diabetes, obesity, and depression, among others, which need critical care during their hospitalization.

The prevalence of end-stage renal disease (ESRD), worldwide, is further increasing at a significant rate, resulting in chronic kidney disease (CKD).

In 2017, in the United States, around 30 million people (15% of US adults) were found suffering from chronic kidney disease (CKD). CKD was found to be more common in women (16%) than in men (13%). For patients undergoing dialysis treatment, the ideal method of vascular access is through an arteriovenous fistula (ANF), by referring to a nephrologist about replacement therapy.

The prevalence of diabetes, increasing rates of road accidents, and an increasing number of surgical procedures are expected to drive the market. Increasing demand for advanced techniques, such as needleless administration of drugs is also a vital driver for this market. Every day many healthcare workers handle drugs in hospitals and other healthcare centers. Despite precaution measures availability, there remains a risk of exposure to these drugs during procedures. Such exposures may occur through, ingestion, absorption, accidental inhalation, or dermal contact of a minimal amount of these drugs which may lead to a variety of health problems.

The advent of COVID-19 had a positive impact on the market of vascular access systems as it became an integral part of the treatment procedures that were followed during the period to cure the patients. Moreover, WHO declared COVID-19 a pandemic as the increase in the number of cases was exponential in the initial months. The medical authorities advised the hospitals and other such medical institutions to stock up the requirements to never run out of supplies during the treatments, which in turn, increased the demand for vascular access systems in the year 2020.

Innovations in the sector have brought down the costs of these products in recent years and the trend is expected to continue during the forecast period.

The market has been shifting towards less expensive catheter devices that tend to have lower rates of failure. The midlines and extended dwell catheters are emerging as lower-cost alternatives which results in a downward force on market value. Both of these catheters are expected to continue growing substantially as clinicians continue to search for solutions that are less invasive than PICCs but provide a longer dwell time than PIVCs. Concerns about catheter-related infections and failures have been applying significant downward pressure on the vascular access market. Many central line catheters are associated with high infection rates, and treating any infections or complications caused by a catheter can be costly and time-consuming for the facility.

As such, clinician preference has trended towards alternative modes of access that have lower complication rates, such as using AV fistula instead of long-term dialysis catheters. As a result of concerns about catheter-related infections and complications, many new vascular access accessories are expected to grow rapidly. Vascular access visualization technologies, such as ultrasound, vein visualization, or tip-placement devices, are intended to bolster catheter performance by improving rates of successful placements, decreasing cases of dislodgment caused by improperly placed catheters, and reducing cases of needle stick injury by lowering the number of attempts required per catheter.

Market Segmentation:

  • By Product

Peripherally Inserted Central Catheter (PICC)

Non-Tunneled Central Catheter

Tunneled Catheter

Port Catheter

  • By Application

Intravenous Antibiotic Treatment

Blood Transfusion

Long-Term IV Feeding

Chemotherapy

Others

  • By End User

Hospitals and Clinics

Ambulatory Surgical Centers

Catheterization Labs

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • UK
  • Others

Middle East & Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Vascular Access Systems Market Analysis, by Product

  • 5.1. Introduction
  • 5.2. Peripherally Inserted Central Catheter (PICC)
  • 5.3. Non-Tunneled Central Catheter
  • 5.4. Tunneled Catheter
  • 5.5. Port Catheter

6. Vascular Access Systems Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Intravenous Antibiotic Treatment
  • 6.3. Blood Transfusion
  • 6.4. Long-Term IV Feeding
  • 6.5. Chemotherapy
  • 6.6. Others

7. Vascular Access Systems Market Analysis, by End-user

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Catheterization Labs

8. Vascular Access Systems Market Analysis, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Edwards Lifesciences Corporation
  • 10.2. Baxter International Inc.
  • 10.3. C.R. Bard, Inc.
  • 10.4. Fresenius Medical Care AG & Co. KGaA
  • 10.5. Becton, Dickinson and Company
  • 10.6. Teleflex Incorporated
  • 10.7. Medtronic PLC
  • 10.8. B.Braun Melsungen AG
  • 10.9. Smiths Medical
  • 10.10. Biomerics